ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

284
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
331 Views
Share
03 Sep 2021 18:03

The Stocks to Own in Asia – Vol. 34

Our research team constantly reviews the Asian markets to try to find interesting ideas based on Fundamentals or Valuation or Momentum or Risk or...

Share
08 Aug 2021 07:56

China Healthcare Weekly (Aug.6)

The insight mainly analyzed increasing short-term volatility in healthcare sector by newly released education policy, Nanjing COVID-19 outbreak,...

Logo
422 Views
Share
06 Aug 2021 10:39

Hong Kong Buybacks: HK$350m Buyback by Xinyi Glass

We highlight the top 3 companies that repurchased the most shares from the market were Xinyi Glass (868 HK), New World Development (17 HK), and...

Logo
437 Views
Share
x